Embecta Corp.EMBC
What Embecta Corp. does.
Embecta Corp. (also referred to herein as "Embecta") is a leading global medical device company, primarily focused on providing solutions to improve the health and well-being of people living with diabetes. All references in this Form 10-K to "Embecta", "the Company", "we", "our" or "us" refer to Embecta Corp., a Delaware corporation, and its subsidiaries, unless otherwise indicated by the context.
Building on our 100-year centennial, we believe that our products have become one of the most widely recognized and respected brands in diabetes management throughout the world. We estimate that our products are used by more than 30 million people in over 100 countries for insulin administration and to aid with the daily management of diabetes.
We have a broad portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Our conventional pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. We also sell safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Our conventional and safety pen needles are compatible and frequently used with widely available pen injectors in the market today. In addition to pen needles, we sell sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. We also sell safety insulin syringes, which have a sliding safety arm that can be activated with one-hand after the injection to help protect healthcare workers from needlestick injuries.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | $1.2B | $1.1B | $1.1B | $1.1B | $1.1B |
| Net income | $427.6M | $414.8M | $223.6M | $70.4M | $78.3M | $95.4M |
| Free cash flow | $456.6M | $419.5M | $388.6M | $41.2M | $19.9M | $182.4M |
More on EMBC.
- Embecta Corp. summary
- Embecta Corp. financial statements
- Embecta Corp. key metrics
- Embecta Corp. health scores and style box
- Embecta Corp. earnings
- Embecta Corp. dividends
- Embecta Corp. valuation
- Embecta Corp. ownership and insiders
- Embecta Corp. peers
Figures from Embecta Corp.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.